The microbiome is one of the most active, exciting research areas in biotechnology and a source of enormous commercial potential. With a number of high-profile, human microbiome-based therapeutics in clinical trials, the first crop of microbiome drugs could launch as early by 2018. IP Pragmatics has a wide range of experience across the biotech sector, and we felt that a comprehensive analysis of the market developments and intellectual property landscape would be a timely addition to this promising field.
